Skip to main content

National Institutes of Health (NIH)

NIAMS P30 Centers Program (P30 - Clinical Trial Not Allowed)

Apply to Internal Competition // Limit: 1 // Tickets Available: 1 

Limiting Language
Only one application per institution is allowed.

Program Description
The overall goal of this program is to accelerate scientific discovery, improve research efficiency, and enhance the translation of research findings into improved health outcomes. Centers funded under this program will also foster multidisciplinary collaboration, support workforce development across career stages, and promote training in emerging areas such as data science, artificial intelligence, and implementation research. The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) requests applications for the NIAMS P30 Centers Program to support integrated research Centers within its mission areas of skin biology and diseases; bone, muscle, and orthopaedic research; and rheumatic diseases.

The NIAMS P30 Centers Program supports Centers that provide coordinated research infrastructure, shared resources, and methodological expertise to advance basic, translational, and clinical research.

These Centers are expected to integrate state-of-the-art research resources with capabilities that support clinical and translational research, including the development, testing, and dissemination of novel analytical methods, study designs, outcome measures, and data-driven approaches.

Full sponsor guidelines are linked here.

Funding Type
External Deadline
2/1/2027
Internal Deadline
Internal Time
5:00PM
Solicitation Type

Diabetes Research Centers (P30 Clinical Trial Optional)

Apply to Internal Competition // Limit: 1 // Tickets Available: 1

Limiting Language
Only one application per institution is allowed, as defined in Section III. 3. Additional Information on Eligibility. 

Please note, under Section III. 3, it states, "Applicant organizations may submit more than one application, provided that each application is scientifically distinct". NIH has clarified the first statement on limiting language, indicating a limit of one, is the correct one.

Purpose of Funding Opportunity
This Notice of Funding Opportunity (NOFO) invites applications for Diabetes Research Centers (DRCs) that are designed to support and enhance the national research effort in diabetes, its complications, and related endocrine and metabolic diseases. The purpose of this Centers program is to bring together basic and clinical investigators to enhance communication, multidisciplinary collaboration, and effectiveness of ongoing research in Diabetes Research Center topic areas. By providing shared access to specialized technical resources (research cores) and supporting a Pilot and Feasibility Program (P&F), DRCs are intended to create an environment that provides the capability for accomplishments greater than those that would be possible by individual research project grant support alone. New Center programs that bring in new approaches, propose unique scientific themes, or provide innovative resources are encouraged. Emphasis will be placed on Center programs that propose enhanced synergies with other NIDDK-funded programs as well as providing a rich mentoring environment for future diabetes researchers. 

Funding Type
External Deadline
1/27/2027
Internal Deadline
Internal Time
5:00PM
Solicitation Type

Limited Competition: NIH Research Evaluation and Commercialization Hubs (REACH) (SB0 Clinical Trial Optional)

Institutionally Coordinated via Tech Launch Arizona, please contact Doug Hockstad // Limit: 1

 

Limiting Language
Only one application per institution (normally identified by having a unique NIH IPF number) is allowed.

The primary applicant organization must be a university or other research institution that participates in the NIH STTR program. Participation means that a university or other research institution has been a formal partner to a small business on an STTR award. Many NIH-supported universities or other research institutions will be eligible. Please contact the Scientific/Review staff listed below for clarification.

Purpose
This Notice of Funding Opportunity (NOFO) announces the renewal of the NIH Research Evaluation and Commercialization Hub (REACH) program, established to facilitate and accelerate the translation of academic biomedical discoveries into products that improve patient care and public health. Through this program, NIH will provide the qualifying institutions with the funds to seed the creation of academic entrepreneurship Hubs. Hubs will be responsible for providing innovators with both the initial investment and resources to support the proof-of-concept work and the mentorship in product development and commercialization needed to develop high priority technologies within the NIH's mission. Funded Hubs are intended to work as a consortium to enable: (1) the infrastructure for identifying the most promising technologies, (2) funding for product definition studies (e.g. feasibility studies, prototype development, proof-of-concept studies) provided to individual researchers, (3) access to resources and expertise in areas required for early stage technology development (including scientific, regulatory, reimbursement, business, legal, and project management), and (4) skills development and hands-on experience in entrepreneurship. Establishing public-private partnerships and providing additional non-federal funds will be critical for success. This is a Notice of Funding Opportunity (NOFO) for a Limited Competition that will invite applications from eligible organizations to apply. Please see Section III. Eligibility for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered for funding.
 

Research Category
Funding Type
External Deadline
11/10/2026
Solicitation Type

Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)

No Applicants // Limit: 1 // Tickets Available: 1

Limiting Language 
Only one application per institution (normally identified by having a unique entity identifier (UEI) number or NIH IPF number) is allowed

Purpose
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications for research on novel therapies for adult glioblastoma (GBM). The goal is to improve the treatment of adult GBM by developing novel effective agents that can cross the blood brain barrier (BBB) and testing them clinically. Successful early-stage trials of new drugs from this NOFO would transition seamlessly to later stage trials using well-established NCI clinical trial mechanisms.

To implement this concept, a highly collaborative GBM Therapeutics Network (GTN) of cross-cutting teams will be established, each team capable of driving therapeutic agent(s) from pre-clinical development, through investigational new drugs (IND) studies, into pilot clinical studies in humans. Appropriate therapeutic agents include: (1) novel agents or (2) agents or combinations approved for other indications and repurposed for treatment of GBM following appropriate preclinical studies. The scope of the NOFO, from late pre-clinical through early (Phase 0/1) clinical studies, uniquely spans a gap in the GBM drug development process.

Funding Type
External Deadline
10/1/2026

Cooperative Centers for Experimental Hematology (CCEHs) (U54- Clinical Trial Not Allowed)

No Applicants // Limit: 1 // Tickets Available: 1

Limiting Language
Applicant organizations may submit only one application.

Purpose
The purpose of this Notice of Funding Opportunity (NOFO) is to invite applications for Centers within the NIDDK Cooperative Centers of Experimental in Hematology (CCEH) Program. Each Center will support one to three Biomedical Research Cores and an Administrative Core, including an Enrichment Program. Each Center is expected to work collaboratively with NIDDK, the Hematology Coordinating Center (HCC), and the other CCEH Centers. The CCEH Program is designed to increase access to critical research resources and expertise unique to nonmalignant hematology research. By providing innovative technology, resources, and expertise to the greater hematology research community, the program will serve as a national hub, aimed at recruiting and retaining both junior scientists just beginning their careers in the field as well as established investigators from other domains.

Funding Type
External Deadline
9/30/2026

Integration of Nutrition Training into Health Care Education Challenge

Limit: 1 // Tickets Available: 0 

S. Dahmer (Andrew Weil Center for Integrative Medicine)

Limiting Language
Only one entry per institution is permitted, either as an individual entry or as a partnership entry with other institution(s). Two or more institutions that have formed close collaborations to enhance nutrition education across the institutions may submit to this Challenge as a partnership.

Overview
The National Institutes of Health (NIH) Office of Nutrition Research (ONR) announces the “Integration of Nutrition Training into Health Care Education” Challenge. ONR’s mission is to stimulate innovative research to address the complexities of nutrition, its ecology, and its critical role in health across the lifespan for all. The goal of this challenge is to identify, evaluate, and promote effective, scalable, and evidence-based approaches to integrating nutrition training into medical and nursing education, including both established programs and emerging models with strong potential for dissemination. The total prize purse from NIH for this Challenge is up to $2,100,000.

Development of Collaborative Research Facilities or Research-Resource Facilities (C06 Clinical Trial Not Allowed)

Institutionally Coordinated // Limit: 2 (one BRF and one HRF)

Limiting Language
Only one application per institution (identified by NIH IPF number) is allowed.

This solicitation spans two programs, Biomedical Research Facilities (BRF) and HIV/AIDS Research Facilities (HRF). Each institution is permitted one application per program, provided they are not overlapping, for a total of two total institutional proposals per deadline. 

Funding Opportunity Purpose
This Notice of Funding Opportunity (NOFO) solicits applications to develop shared-use research facilities or research-supporting facilities that enable collaborative research and benefit broad research communities at large. The NOFO supports two existing construction programs: the Biomedical Research Facilities (BRF) program and the HIV/AIDS Research Facilities (HRF) program.

The BRF program supports the construction or modernization of biomedical research facilities that advance basic, translational, clinical, or behavioral science research in all areas. Intended facilities include shared research spaces, core facilities, biorepositories, or other shared-use resource facilities that serve a broad scientific community with a significant, long-term impact on biomedical research.

The HRF program funds the development of HIV/AIDS research or research-supporting resources that the empowered research activities must align with the NIH Office of AIDS Research (OAR) priorities, as outlined at OAR HIV/AIDS Research Priorities, including research focusing on the long-term health consequences of HIV infection.

NIH encourages applications from institutions across all geographic regions of the country, including Institutions of Emerging Excellence (IEE) in biomedical research, to strengthen the nation’s research capacity.

Nutrition Obesity Research Centers (NORCs) (P30 Clinical Trial Optional)

Limit: 1 // Tickets Available: 0

F. Speilberg (Family, Community and Preventive Medicine, COM-P)

Limiting Language
Only one application per institution (normally identified by having a unique DUNS number or NIH IPF number) is allowed, provided that each application is scientifically distinct.

Purpose
This Notice of Funding Opportunity (NOFO) invites applications from institutions/organizations that propose to establish core centers that are part of an integrated and existing program of nutrition and/or obesity research. The Nutrition Obesity Research Centers (NORC) program is designed to support and enhance the national research effort in nutrition and obesity. NORCs support three primary research-related activities: Research Core services, a Pilot and Feasibility (P and F) program, and a Scientific Catalyst program. All activities pursued by Nutrition Obesity Research Centers are designed to enhance the efficiency, productivity, effectiveness, and multidisciplinary nature of research in nutrition and obesity.

Funding Type
External Deadline
10/20/2026

Research Centers in Minority Institutions (RCMI) Coordinating Center (U24 - Clinical Trial Optional)

No Applicants // Limit: 1 // Tickets Available: 1 

Limiting Language
Only one application per institution (normally identified by having a unique UEI number or NIH IPF number) is allowed.

Purpose
In response to a longstanding congressional mandate (P.L. 98-619, Departments of Labor, Health and Human Services, and Education and Related Agencies Appropriation Act, 1985), NIMHD invites applications from eligible institutions to establish a national coordinating center (CC) for the Research Centers in Minority Institutions (RCMIs) initiative. The RCMI CC will coordinate activities across funded RCMI U54 Centers, prospectively evaluate the overall RCMI program, and serve as a national resource to help these centers achieve their primary goals. The RCMI CC will be responsive to requests generated by RCMI site key personnel, NIMHD, NIH, the scientific community, and the general public. 
 

Funding Type
External Deadline
8/7/2026

NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) - PAR-23-286, PAR-23-287

Limit: 4* (see below) // Tickets Available: 2

Cancer Data Science // Limit: 1 // Tickets Available: 0
E. Ochoa Mora (Epidemiology and Biostatistics)

Cancer Control Science // Limit: 1 // Tickets Available: 0
J. Llavona-Ortiz (Cancer Center)

Molecular Precision/Cancer Prevention // Limit: 1 // Tickets Available: 1 

Other Cancer Research // Limit: 1 // Tickets Available: 1

Limiting Language
Each eligible institution (defined as having a unique UEI number or NIH IPF number) may submit up to a combined total of four applications (one in Cancer Data Science, one in Cancer Control Science, one in Molecular/Precision Cancer Prevention, and one in Other Cancer Research) to any companion NOFO or any combination of companion NOFOs (PAR-23-286, PAR-23-287, and/or PAR-23-288 (archived)).

Scientific Areas

  • (A) Cancer Data Science: For the purposes of this K99/R00 award, cancer data science is defined as an interdisciplinary field of inquiry in which quantitative and analytical approaches, processes, and systems are both developed and used to extract knowledge and insights from increasingly large and/or complex sets of data. This includes cancer-focused data integration and visualization, systems biology, artificial intelligence, machine learning, informatics, genomics, precision oncology, and developing analytics for epidemiological or biostatistical studies.
  • (B) Cancer Control Science: For the purposes of this K99/R00 award, cancer control science is defined as basic and applied research in the behavioral, social, and population sciences to create or enhance interventions that, independently or in combination with biomedical approaches reduce cancer risk, incidence, morbidity, and mortality, and improve quality of life. This includes research in epidemiology, behavioral sciences, health services, surveillance, cancer survivorship, and healthcare policy.
  • (C) Molecular/Precision Cancer Prevention: For the purpose of this K99/R00 award, early translational research in cancer prevention is defined as basic research to understand mechanisms of cancer formation, development and progression of cancer precursors, and to translate basic biological knowledge into novel human interventions and human-centered adaption of current interventions with the potential to reduce cancer risk, incidence, and mortality, and improve quality of life. This includes but is not limited to research in molecular and systems biology, diagnostics, vaccine and drug development, pharmacology, and biomedical engineering.
  • (D) Other Cancer Research: For the purposes of this K99/R00 award, "Other Cancer Research" includes all scientific fields supported by the NCI that are not included in (A), (B) or (C). Applicants proposing research in (D) "Other Cancer Research" may apply only if it is reasonable to expect their candidates to transition to independence with an abbreviated period of mentored research training beyond their original doctoral degrees."
Funding Type
External Deadline
10/14/2026